Organization · Venture Capital
Mirae Asset Capital Life Science
Mirae Asset Capital Life Science is a U.S.-based venture capital firm focused on investing in life sciences and biotechnology companies, particularly those in Series A and B stages. The firm emphasizes clinical proof of concept and innovative therapeutic modalities.
Overview
What Mirae Asset Capital Life Science does
What Mirae Asset Capital Life Science is
Mirae Asset Capital Life Science is a U.S.-based venture capital firm focused on investing in life sciences and biotechnology companies, particularly those in Series A and B stages. The firm emphasizes clinical proof of concept and innovative therapeutic modalities.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- May 3, 2026
Official channels
Find Mirae Asset Capital Life Science elsewhere
Open the official website or a supported primary organization account.
Capability profile
Mirae Asset Capital Life Science as a funder
Investment thesis
Mirae Asset Capital Life Science invests in companies delivering safe and effective treatments quickly to patients, focusing on clinical value and innovative modalities.
Focus narrative
The organization primarily invests in Series A and B companies entering clinical trials, with a modality-agnostic approach to therapeutics and an opportunistic stance on diagnostics. Key therapeutic sectors include Oncology, Immunology, Cardiovascular/Metabolic, Central Nervous System/Ophthalmology, and Rare/Genetic Diseases, with a particular interest in digital health applications utilizing AI and machine learning.
Value beyond capital
Mirae Asset Capital Life Science leverages its global biotech network and expertise in life sciences to support portfolio companies in achieving clinical proof of concept and navigating the complexities of drug development.
Terms and economics
- Typical check
- $1,000,000–$10,000,000
Focus and fit
- Stages
- Seed · Series A · Series B · Series C
- Sectors
- Biotech · Healthcare · Diagnostics · AI
- Regions
- Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Accent Therapeutics: Developing small molecule precision cancer therapies targeting critical intracellular dependencies across multiple cancer types. Candid Therapeutics: Focused on transformative drugs, starting with bispecific T-cell engager antibodies for autoimmune diseases. Attovia: Developing biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY™ platform. Aktis Oncology: Dedicated to alpha radiopharmaceuticals for cancer care. BioNTech: Focused on immunotherapies for global health improvement. Septerna: Innovating in GPCR-targeted drug discovery.
Common questions
What to know about Mirae Asset Capital Life Science
Upseed classifies Mirae Asset Capital Life Science under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 3, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.